114 results
10-K/A
2022 FY
ATNXQ
Athenex, Inc.
28 Apr 23
Annual report (amended)
8:10am
of the Scientific Advisory Counsel for Mallinckrodt Pharmaceuticals, member of the Hepatology Counsel for Novartis, and Chairman of the Data Safety and Management … of the Data Monitoring and Safety Board and Protocol Review Board for the Clinical Trial Network of the National Institute on Drug Abuse of the U.S. National
8-K
EX-99.1
ATNXQ
Athenex, Inc.
3 Nov 22
Athenex Provides Third Quarter 2022 Financial Results and Business Update
7:10am
innovative, first-in-class NKT cell therapy platform with potential for improved efficacy, safety, and accessibility over current cell therapy approaches … :
Phase 1 GINAKIT2 study dose escalation, safety, and preliminary efficacy data update in 1H 2023
KUR-502:
Next clinical trial data update from
DEFA14A
ATNXQ
Athenex, Inc.
11 Oct 22
Additional proxy soliciting materials
8:31am
candidates; the Company’s ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates
8-K
kgeaxzp9p 77w2
3 Oct 22
Entry into a Material Definitive Agreement
4:16pm
8-K
EX-10.1
1bdvz63c5q fm7
15 Aug 22
Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants
12:00am
424B5
yfbw24kgbq x10b
12 Aug 22
Prospectus supplement for primary offering
3:55pm
424B5
u013c xfyse6
10 Aug 22
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
ibb89ejip1lcne8 8v
28 Jul 22
Athenex Provides Second Quarter 2022 Financial Results and Business Update
7:05am
8-K
psob1xi0i0i0
11 Jul 22
Expected sale proceeds of approximately $19.0 million
4:15pm
8-K
EX-99.1
aw7qxn9n05qn2v
11 Jul 22
Expected sale proceeds of approximately $19.0 million
4:15pm
8-K
EX-99.1
o5czasy fmq7
24 Jun 22
Company executes on strategy to extend cash runway by monetizing non-core assets
4:31pm
8-K
v1lz9o
24 Jun 22
Company executes on strategy to extend cash runway by monetizing non-core assets
4:31pm